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Abstract:  
Background & Aims: There are no approved treatments for pediatric non-alcoholic fatty 
liver disease (NAFLD) and there is a lack of consensus on the best outcome measure for 
randomized controlled trials. We performed a systematic review of treatments tested for 
pediatric NAFLD, the degree of heterogeneity in trial design, and endpoints analyzed in these 
studies. 
 
Methods: We searched publication databases and clinical trial registries through January 7, 
2018 for randomized controlled trials (published and underway) of children (<18 years) with 
NAFLD. We assessed improvements in histologic features, radiologic and biochemical 
markers of reduced fibrosis, metabolic syndrome parameters, and adverse events. The quality 
of the trials was assessed using a modified version of the Cochrane risk of bias tool.  
 
Results: Our final analysis included 21 randomized controlled trials, comprising 1307 
participants (mean age, 12.6 years; 63% male; mean duration of intervention, 8 months). 
Most studies evaluated weight loss with lifestyle intervention (n=8), oral polyunsaturated 
fatty acid treatment (PUFAs, n=6), or oral antioxidant treatment (n=7). Biomarkers of 
NAFLD decreased with weight loss, but most studies did not include histologic data. Trials of 
antioxidants were heterogeneous; some reported reduced histologic features of steatohepatitis 
with no effect on triglycerides or insulin resistance. PUFAs and probiotics reduced radiologic 
markers of steatosis, insulin resistance, and levels of triglycerides. Only 38% of the trials had 
biopsy-proven NAFLD as an inclusion criterion. There was heterogeneity in trial primary 
endpoints; 10 studies (48%) used levels of aminotransferases or ultrasonography findings as a 
primary endpoint and only 3 trials (14%) used histologic features as the primary endpoint. 
We identified 13 randomized controlled trials that are underway in children with NAFLD. 
None of the protocols include collection of liver biopsies; 9 trials (69%) will use magnetic 
resonance imaging quantification of steatosis as a primary outcome. 
 
Conclusion: In a systematic review of published and active randomized controlled trials of 
children with NAFLD, we found a large amount of heterogeneity in study endpoints and 
inclusion criteria. Few trials included histologic analyses. Antioxidants appear to reduce 
some features of steatohepatitis. Effects of treatment with lifestyle modification, PUFAs, or 
probiotics have not been validated with histologic analysis. Trials that are underway quantify 
steatosis magnetic resonance imaging—outcomes are anticipated. 
 
KEY WORDS: MRI, NASH, clinical trial design, progression, response 
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Introduction 
 
 
Pediatric non-alcoholic fatty liver disease (NAFLD) refers to the spectrum of hepatic 
steatosis (‘simple steatosis’ or non-alcoholic fatty liver) and non-alcoholic steatohepatitis 
(NASH), with or without fibrosis1. NAFLD affects 5.5-10.3% children world-wide2 and is 
closely related to the metabolic syndrome3; 34% of obese children have evidence of NAFLD2. 
With the acceleration in rates of pediatric obesity, the burden of pediatric NAFLD will 
increase similarly to that of adult NAFLD4. There is evidence that pediatric NAFLD is 
associated with increased mortality5 and it is generally accepted that fibrosis is likely to be 
the major predictor of liver-related outcomes, as it is in adults with NAFLD6, however the 
main long-term burden of NAFLD for patients is cardiovascular disease7. These clinical 
events will mainly manifest in adulthood, therefore altering the disease course of pediatric 
NAFLD may improve outcomes in later life. 
 
NAFLD is identified either through screening of obese children or incidentally on imaging or 
with abnormal LFTs, but it cannot be formally diagnosed or staged without liver biopsy8,9. 
Current management focuses on weight loss through a combination of caloric restriction and 
physical exercise10. There are no licensed or uniformly recommended pharmacological 
therapies and bariatric surgery is only recommended if there are additional comorbidities11. 
The conclusions of other systematic reviews in the field have been limited to specific 
treatment modalities12–14,pharmacological options15–17, or have no distinguished children 
from adults18. 
 
One of the biggest challenges in designing a robust RCT in pediatric NAFLD is the lack of 
societal consensus on appropriate primary outcome measures. Liver biopsy is the gold 
standard for diagnosis and assessment8. There are no non-invasive markers or imaging 
modalities that are considered an equivalent for diagnosis or assessing response to 
treatment19. However, there can be reluctance from parents and ethical review boards for 
paired biopsies in pediatric clinical trials. 
 
Our systematic review aimed to determine the most effective treatment for pediatric NAFLD 
and assess the degree of heterogeneity in trial design, and whether it may limit the 
conclusions drawn from RCTs. To address these issues, we performed a systematic review 
of randomized controlled trials (RCTs) in pediatric NAFLD, including a comprehensive 
assessment of trial quality and design. In addition, we assessed future RCTs based on data 
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from clinical trials registries. By inclusion of all treatment modalities and ongoing trials we 
aimed to achieve a broader view than had been covered in systematic reviews to date. 
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Materials and Methods 
 
The systematic review was prospectively registered on PROSPERO (registration number 
CRD42016048084) and can be accessed on http://www.crd.york.ac.uk/PROSPERO. 
  
Data sources and extraction: 
 
The databases searched included MEDLINE OvidSP, Cochrane CENTRAL Register of 
Controlled Trials, PubMed, clinicaltrials.gov, and World Health Organization International 
Clinical Trials Registry. Search terms included: “child”, "pediatric”, "fatty liver", and “clinical 
trials” (see Supplementary Methods for full details of databases and search terms). Finalised 
searches were performed on January 7th 2018 and independently verified by two individuals 
(JPM, GYT). Six primary authors were contacted directly to verify results and methodology of 
their manuscripts.  
 
Potentially relevant titles and abstracts were screened, and then full papers were reviewed 
for inclusion, independently in duplicate by two authors (GYT and JPM). Data extraction was 
also independently performed by two authors in duplicate (GYT and JPM). Differences were 
resolved by discussion with VN and MJA.  
 
Selection of published studies: 
 
The inclusion criteria were published RCTs of children given any intervention that aimed to 
improve NAFLD (NASH, Fibrosis), which included participants ≤18 years of age and with a 
diagnosis of NAFLD, either by radiological or histological modalities. The definition of NAFLD 
included the presence of hepatic steatosis with a negative viral (hepatitis B and C virus), 
metabolic (ceruloplasmin, ferritin, alpha-1-antitrypsin) and auto-immune screen 
(immunoglobulins, anti-nuclear antibody, anti-smooth muscle antibody, and anti-liver kidney 
microsomal antibody). The exclusion criteria were articles not written in English, non-
randomised trials, those with secondary causes of hepatic steatosis (i.e. monogenic 
disorders, lipodystrophy, steroid-induced) and post liver transplantation. Reviews, letters, 
case reports/series and editorials were excluded. There were no restrictions on gender, 
ethnicity, numbers of participants or year of publication. 
 
Selection of active/ongoing registered clinical trials:  
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Clinical trials registries were searched, including clinicaltrials.gov, IRCTN etc. The inclusion 
and exclusion criteria were as described above, in addition to trial status as active, recruiting, 
not completed, or not reported. 
 
Outcome measures: 
 
The primary outcome assessed was mean difference in Kleiner’s20 histological fibrosis. 
Secondary histological outcomes included steatosis, (lobular/portal) inflammation, and the 
combined NAFLD Activity Score (NAS)20. If pre- and post-treatment liver histology was not 
performed, then biochemical response (alanine aminotransferase (ALT)) or radiological 
improvement (improvement on ultrasound (US), magnetic resonance imaging (MRI), 
magnetic resonance spectroscopy (MRS)) were assessed. The effect on metabolic 
syndrome parameters was evaluated using insulin sensitivity (homeostatic model of 
assessment of insulin resistance (HOMA-IR)) and triglycerides (TG). Age-/sex-standardised 
weight loss and adverse events were also assessed. Primary outcome (or end-point) method 
was assessed for published and active, registered RCTs. 
 
Quality assessment: 
 
The quality of RCTs was assessed using a modified version of the Cochrane risk of bias 
tool21, attributing 1 point to each item, with a total score of 7, as for previous meta-analyses 
in the field22. In addition, calculation of sample size a priori was attributed 1 point, giving a 
total quality score of 8. Trials with a score 6, 7, or 8 were defined as high-quality (HQ). 
Compliance with CONSORT 2010 publication checklist23 was assessed, attributing 1 point to 
each item, or 0.5 to each half-item (total score 25). A bibliometric analysis was performed to 
indicate the impact of each RCT, including number of citations per month since publication. 
 
Data synthesis and analysis: 
 
Analysis was performed using RevMan 5.324 and in accordance with the Cochrane 
Handbook of Systematic Reviews25. Inter-assessor agreement on study inclusion and quality 
was measured using intraclass correlation coefficients (ICC).  
 
Results 
 
Study characteristics and quality assessment: 
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Database searches identified 10,115 published articles. 9,793 were excluded at screening 
stage and 299 were excluded on full-text review (Supplementary figure 1). The main reasons 
for exclusion on full-text review were lack of relevance (152/299) and non-randomised or 
non-controlled trials (130/299). Two pairs of studies (refs 11 & 12 and refs 13 & 14) reported 
the results of the same trial. Agreement between the two assessors was 0.86 (95% CI 0.74-
0.98) for study inclusion and 0.90 (95% CI 0.76-0.96) for quality assessment. Of the 21 
studies included 11/21 (52%) were of high-quality with a score of 6 or more (low risk of bias) 
and 8/21 (38%) were of low quality, with a score below 5 (Tables 1 & 3).  
 
A total of 1307 participants were studied, with a mean age 12.6 years, 63% male, and a 
mean intervention duration of 8 months (range 1-24 months). Quality assessment found 
random sequence generation and allocation concealment were adequate in 48% (10/21). 
Blinding was adequate in 62% (13/21) and sample size was calculated a priori in 48% (10/21) 
of studies (Supplementary figure 2). Median CONSORT Reporting score was 20.5 (range 
12.5-24.5) with high quality reporting (score 23 or greater) in 33% (7/21, Supplementary 
table 1). The most frequent areas of insufficient reporting were details of randomisation, trial 
registration, availability of full protocol, and identification as an RCT in the title 
(Supplementary figure 3). 4 studies did not define a primary outcome and 1 did not report 
findings of their primary outcome. 7/18 (39%) of RCTs did not meet their primary outcome 
(when it was defined), including 4 where sample size was calculated a priori. 
 
Pre and post-treatment histology was available for 5 studies27,29–32, however in 229,32 of these 
5 a post-treatment biopsy was only performed for the intervention group, not for the control 
group. 
 
Study design and selection of end-points 
 
Three out of 21 (14%) RCTs used liver biopsy as their primary end-point27,31,33 
(Supplementary table 1, and Figure 1), namely improvements in NAS and fibrosis stage; with 
two further studies using histology as a secondary outcome measure.  
 
Of the remaining studies, primary end-points included change in ALT or AST (5/21; 24%) 
and ultrasonographic echogenicity (5/21; 24%). No studies used novel biomarkers of NASH 
or non-invasive scoring systems for NASH or fibrosis in their primary outcome.  
 
8/21 (38%) of studies used biopsy-proven NAFLD as an inclusion criteria, with the remainder 
diagnosed non-invasively. 
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Study interventions: 
 
Dietary intervention (Tables 1 and 2) 
Three RCTs34–36 were included (total 47 participants; 1/3 high quality) with radiologically 
diagnosed NAFLD that assessed low fructose (or low glycaemic load) diets for 4 weeks to 6 
months. Vos et al.34 performed a pilot study of low fructose diet by exclusion of sugar-
sweetened beverages (SSB) and high fructose corn syrup (HFCS) for 6 months, compared 
to a low-fat diet, without caloric restriction. Ramon-Krauel et al.35 restricted carbohydrate 
(CHO) to 40% in the intervention group ab libitum, compared to a standard ‘low fat’ diet, and 
Jin et al36 gave participants 3 glucose-containing beverages per day instead of fructose-
containing beverages. Outcome measures used were change in liver enzymes (in all 3/3) 
and change in hepatic fat on MRS (2/3; 66%); none had post-treatment histology. In both of 
the 6 month studies, there was similar reduction in ALT, and improvement in hepatic fat on 
MRS in both low-fat and low-fructose treatment arms. 4 weeks of low-fructose had no effect 
on ALT or MRS. Therefore these RCT do not provide any evidence for benefit of low-
fructose diet over low-fat diet on non-invasive markers of NAFLD, however they are small 
and have no untreated control group for comparison. 
 
Weight loss by lifestyle intervention (Tables 1, 2, and 3) 
Eight RCTs27,32,37–42 were included (453 participants; 2/8 high quality), of which 3 had a 
baseline biopsy to describe the cohort and 1 study was in exclusively NASH patients. 
Duration ranged from 1 – 24 months, with 6/8 of 6 months or longer. Only one study 
compared lifestyle intervention to no treatment (i.e. a true control) with the remaining 6 RCT 
using lifestyle plus placebo against lifestyle plus drug. 
6/8 studies used a low-fat diet (23-30%), caloric restricted (25-30 kcal/kg/day) diet with and 
exercise (from 30min 3x per week to 45min per day).  
1 study gave education and advice, whilst Wang et al.38 reported results of a 3-arm RCT, 
which included a strict 1-month lifestyle camp (3 hrs/day aerobic exercise, -250 kcal/day) 
versus unstructured lifestyle plus 100mg/day Vitamin E versus no intervention (standard of 
care). 
Outcome measures used were change in liver enzymes (7/8; 88%) and change in 
ultrasonographic echogenicity (7/8; 88%), and post-treatment histology in 1/8 (13%). 
All studies found an improvement in ALT and/or US echogenicity, with or without weight loss.  
Wang et al found 2.5 kg/m2 loss of BMI was achieved in the strict lifestyle group, compared 
to 1.4 kg/m2 in the unstructured lifestyle and vitamin E group. This study was found to be at 
higher risk of bias. 
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Significant weight loss was also achieved in Nobili et al.27, with 2.9 kg/m2 BMI loss at 24 
months. This group was found to have improvement in histological steatosis, lobular 
inflammation, and hepatocyte ballooning, but fibrosis stage was unchanged. 
Vajro et al.37 commented on only 33% compliance with diet and found that diet-compliers 
had improvement in ALT whereas non-compliers had no improvement. Across all studies, 
greater BMI loss was associated with greater improvement in ALT, triglycerides (TG), and 
HOMA-IR.  
Drop-out varied between 0-24% with no adverse effects. 
These RCT suggest that lifestyle modification is safe and when investigated can improve 
histological features of NASH and that greater weight loss is associated with larger 
improvements in ALT as well as markers of metabolic dysfunction. The benefit of weight loss 
over no treatment has not been well described. It is also unclear whether more or sustained 
weight loss is required to improve fibrosis. These conclusions are limited by the lack of true 
control groups, low compliance, and only a single study with post-treatment histology. 
 
Insulin sensitisers: metformin (Tables 3 and 4) 
Four RCTs39,40,43,44 (396 participants; 1 high quality) assessed metformin in non-diabetic 
children. Total daily doses of 500mg-1.5g were used for 4-24 months. 
Three RCTs used change of steatosis on ultrasound as their primary outcome and the 
TONIC trial43 used sustained reduction in ALT as primary outcome with histology as 
secondary outcomes. 
The TONIC trial43 was a 3-armed study that compared placebo, metformin, and vitamin E 
(800IU daily) in children with biopsy-proven. Metformin was no better than placebo in 
achieving sustained reduction of ALT though use was associated with an improvement in 
hepatocyte ballooning compared to placebo (44% vs 21%; p=0.02). The results of the 
vitamin E arm will be discussed under the antioxidants section. 
2/4 (50%) studies found greater improvement in ultrasound echogenicity in with metformin 
use compared to placebo, however statistical significance was not reported. Shiasi Arani et 
al44 also found improvement of radiological steatosis however did not include a placebo arm. 
Across all studies metformin was associated with an improvement in markers of insulin 
resistance and was weight-neutral. 
Drop-out rate on metformin was similar to other assessed interventions (0-24% across 
studies) though mild adverse events (abdominal pain, nausea, diarrhoea) were reported in 
29% vs 22% placebo in one study39 and resulted in 9 discontinuations in another44. 
These studies indicate that metformin improves insulin resistance and may be associated 
with reduced steatosis on ultrasound; it also has potential for histological improvement of 
ballooning degeneration in NASH. It is associated with mild adverse events but its 
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discontinuation rate is no different to lifestyle. These conclusions are limited by the variation 
in outcome measures, lack of placebo control, and low reporting of statistical significance. 
 
Antioxidants: vitamin E 
Six RCTs27,31,37,38,40,43,44 (516 participants; 2 high quality) were included. 3/6 used variable 
dosing of vitamin E compared to placebo (duration 1 – 24 months), 1/6 compared vitamin E 
with different lifestyle interventions (without a direct comparator), 1/6 used vitamin E 
compared to metformin with no placebo; finally, 1/6 used vitamin E plus vitamin C compared 
to placebo. Outcomes used by these studies were: change in liver enzymes (4/6; 66%), 
change in ultrasound steatosis (4/6; 66%), and histology (2/6; 33%), where histology was a 
secondary outcome for the TONIC trial. 
Vitamin E use was associated with improvement in ALT and ultrasound echogenicity but was 
no better than placebo. The vitamin E arm of the TONIC trial43 had improved ballooning and 
NAS compared to control, but, similar to metformin, did not meet its primary end-point of 
sustained ALT reduction. Nobili et al.27 found that vitamin E and vitamin C in combination 
improved NAS, inflammation, and steatosis, but again was no different to control. 
Overall antioxidants were safe, with only 1 withdrawal due to high ALT in a vitamin E group. 
These data suggest that vitamin E shows no significant benefit over placebo on ALT or 
ultrasound though may improve features of NASH. These conclusions are limited by study 
heterogeneity, incomplete reporting, and lack of true placebo controls. 
 
Antioxidants: cysteamine bitartrate 
One high quality RCT31 by Schwimmer et al. assessed use of cysteamine bitartrate delayed 
release (CBDR) 169 in children with NAFLD and NAS ≥4 on biopsy for 24-months. The 
primary outcome was improvement in liver histology. CBDR had no benefit on fibrosis or 
NAS compared to placebo, but improved lobular inflammation and ALT, without change in 
BMI SD. Greater magnitude of effect was found in children weighing <65kg. Adverse events 
were reported in 70% CBDR and 67% of placebo but dropout rate was 14% CBDR, 
compared to 4% in placebo. These data suggest that CBDR may be of benefit in improving 
NASH, particularly in younger adolescents. These conclusions are limited by the inclusion of 
only a single study. 
 
 
Polyunsaturated fatty acids (PUFA, Tables 3 and 4) 
 
Six RCTs29,32,41,45–47 (397 participants; 3 high quality) compared PUFA formulations to 
placebo for 6-24 months. 5/6 studies used various combinations of docosahexaenoic acid 
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(DHA) and eicosapentanoeic acid (EPA) and 1/6 used a combination of DHA, choline, and 
vitamin E (DHA-CHO-VE), including a low dose of vitamin E (39 IU). Outcome measures 
were: liver enzymes in 5/6 (83%), ultrasound echogenicity in 4/6 (66%), one study used MRI 
hepatic fat fraction, and one study used change in plasma fatty acids. 
4/6 (66%) studies found hepatic fat (on MRI) or ultrasound echogenicity was improved with 
PUFA treatment compared to placebo. Whereas only one study found an improvement in 
ALT over placebo. There was improved NAS (steatosis and ballooning) in the DHA-CHO-VE 
arm but this could not be compared to a control group which lacked histological assessment. 
Biopsy was not performed in the control group due to ethical reasons, based on guidance 
from the European Society for Pediatric Gastroenterology, Hepatology and Nutrition8. 
PUFA were safe and well tolerated with drop-out rates comparable to other interventions. 
These data suggest that PUFA improves radiological steatosis but not ALT. It is not possible 
to draw conclusions on improvement of NASH or the optimum dosing/formulation of PUFA. 
 
Polyunsaturated fatty acids with vitamin D (Tables 3 and 4) 
 
One high-quality study33 (41 participants) compared DHA plus vitamin D for 12 months in 
vitamin D deficient (<20ng/dl) children with biopsy-proven NAFLD. Primary outcome was 
change in liver enzymes with post-treatment biopsy was performed in the intervention group 
only, however a retrospective comparison to data from Nobili et al.28 (who received DHA 
500mg alone) was used for assessment of the impact of vitamin D on histology. 
Treatment improved ALT greater than placebo and biopsy suggested that vitamin D 
improved NAS and each of its components without change in fibrosis stage. It should be 
noted that this comparison is retrospective and participants from Nobili et al. were not 
vitamin D deficient. 
No adverse reactions were reported. 
These data suggest that treatment with vitamin D and PUFA in vitamin D-deficient children 
improves ALT but it is not possible to conclude the effect on histology without a direct 
comparator. 
 
 
 
Probiotics 
 
Three RCTs42,48,49 (128 participants, 2 high quality) compared probiotics against placebo. 
Three different probiotic formulations were used for 2 – 4 months. Outcomes used were liver 
enzymes and ultrasound echogenicity for all 3 studies. 
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2/3 (66%) found an improvement in ALT over placebo and 2/3 (66%) found improvement in 
ultrasound echogenicity. There was also improvement in insulin resistance and serum lipids. 
Probiotics were well tolerated with low drop-out, where reported. 
These data suggest that probiotics improve ALT and ultrasound appearances of steatosis, in 
addition to markers of the metabolic syndrome. These data are limited by variation in 
formulation of probiotics and lack of histological data, so it is not possible to comment upon 
fibrosis or NASH. 
 
 
 
 
Active, ongoing clinical trials (Table 5) 
Database search identified 100 potentially relevant ongoing clinical trials (Supplementary 
Figure 4): 66 were not related to pediatric NAFLD and 21 were not RCTs. 
 
13 trials were included (10 in NAFLD, 3 in NASH), involving 6 dietary interventions, 1 
lifestyle intervention, 3 anti-oxidants and 3 others (including losartan) (Table 5). None of the 
identified trials plan to use liver histology as a primary end-point. 9/13 (69%) will use 
quantification of hepatic steatosis on MRI as primary end-point, 4/13 (31%) will use change 
in ALT/AST, and 1/13 (8%) will use novel biomarkers of NASH (cathepsin-D, 
lipopolysaccharide). 
 
One relevant, non-randomised controlled trial in bariatric surgery was identified 
(NCT02412540). Participants undergoing vertical sleeve gastrectomy will be compared to 
those having comprehensive lifestyle intervention with a biopsy at 12-months and the 
primary outcome includes correlation of histological changes in NASH with MR and CK-18. 
 
Discussion 
 
This systematic review of RCTs investigates all therapeutic interventions in pediatric NAFLD. 
Of the 21 RCTs identified consisting of 1307 patients, there was marked heterogeneity in 
study design quality, sample size, duration, outcome measures, and therapeutic intervention. 
Lifestyle interventions and anti-oxidants were the most studied, with an emergence of 
probiotic and PUFA studies in the last 5 years. In contrast to adult RCTs, only 14% of 
pediatric studies included paired histology as outcome measure, with the remainder relying 
on non-invasive markers of NAFLD. 62% of RCTs included children without a biopsy-
diagnosis of NAFLD. On review of both published and active RCTs there has been a general 
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shift from the use of ALT and ultrasound as end-points to MRI quantification of hepatic 
steatosis. 
 
Assimilation of the data provides suggestions antioxidants may improve lobular inflammation, 
PUFA improve radiological steatosis, and probiotics improve ALT as well as ultrasound 
steatosis. However the optimum formulation, dosing, and duration is unclear due to study 
heterogeneity. Evidence suggests further study of PUFA and probiotics is warranted. 
Metformin, PUFA, and probiotics offer greatest benefit on weight loss, insulin resistance, and 
dyslipidaemia, which are pivotal targets in pediatric NAFLD to reduce their future 
cardiovascular risk. 
 
Weight loss through lifestyle intervention is the mainstay of treatment for pediatric and adult 
NAFLD9. It is difficult to assess the magnitude of effect from lifestyle interventions due to 
lack of control groups. In keeping with the findings by Gibson et al.13, there were no RCTs 
that specifically assessed the role of physical exercise on pediatric NAFLD. There was a 
trend towards greater reduction in ALT with greater weight loss, consistent with adult data22. 
 
Lifestyle intervention should remain the primary treatment for pediatric NAFLD, but there is 
insufficient data to recommend any particular dietary or exercise regimen. This review found 
no evidence to support a low-fructose diet, however these were only pilot studies and there 
are several larger RCTs in process. It is also not clear what degree of weight loss is required 
to improve NAFLD, whereby studies with less than 0.4 BMI SD reduction failed to achieve 
any improvement in ALT or ultrasound steatosis. Evidence from bariatric surgery suggests 
that reversal of fibrosis is possible with substantial weight loss50. Further studies of bariatric 
surgery in NAFLD are ongoing. 
 
Our conclusions on diet & lifestyle are similar to those reached by other systematic 
reviews13,14, including Africa et al., who also assessed non-randomised trials. We have 
suggested that antioxidants (as a class) improve lobular inflammation, following results of 
CBDR, which were not available to Sarkhy et al.15 This review found the evidence on PUFA 
to be encouraging but due to variation in formulation and dosing used in trials, our 
conclusions are more measured than those from Chen et al.16  
 
This analysis has highlighted the limitations of the current data for the treatment of pediatric 
NAFLD. Aminotransferases and hepatic steatosis fluctuate during the course of NAFLD22,51, 
do not correlate with histology52, and are not predictive of clinical outcomes in adults. There 
is some recent encouraging data correlating MRI PDFF with fibrosis in adults53 however it 
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has not yet been shown to correlate with liver-related clinical outcomes in adults or children. 
However, histological primary end-points were no more likely to be met than non-invasive 
outcomes. 
 
There are many challenges in RCT design for pediatric NAFLD. Liver biopsy is an invasive 
procedure with potential risks though data also suggests that liver biopsy in obese children is 
safe, with serious complications being rare54. An international consensus should be reached 
on whether quantification of steatosis is a suitable alternative for post-treatment histology in 
RCTs. It is also worthy of consideration that with improved research in serum biomarkers 
and non-invasive imaging techniques, biopsies will be used less frequently in clinical practice. 
 
Conclusion 
Antioxidants improve some histological features of NASH. There is encouraging non-
invasive data for lifestyle modification, PUFA, and probiotics but there is a lack of histological 
data for correlation. RCTs have moved to use of MR quantification of steatosis as a primary 
outcome measure, but the predictive accuracy of MR for clinical outcomes in children 
requires future study. 
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Figure legends 
 
Figure 1. Proportion of RCTs using each outcome measure, by class of intervention. 
 
Supplementary Figure 1. Flow chart for identification of completed, published randomised 
controlled trials in pediatric NAFLD suitable for inclusion. 
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Supplementary Figure 2. Cochrane Risk of Bias scores of RCTs. 
 
Supplementary Figure 3. CONSORT scores of RCTs. 
 
Supplementary Figure 4. Flow chart for identification of ongoing randomised controlled 
trials in pediatric NAFLD suitable for inclusion. 
 
 
Table legends 
 
 
Table 1. Characteristics of published randomised controlled trials of dietary or 
lifestyle intervention for pediatric NAFLD. Maximum Cochrane score is 8, where ≥6 is of 
high quality (HQ). ALT, alanine aminotransferase; BMI, body mass index; DHA, 
docosahexaenoic acid; MRS, magnetic resonance spectroscopy; NA, not assessed; PLA, 
placebo; PUFA, polyunsaturated fatty acids; SD, standard deviations (of BMI, age-/sex-
corrected); US, ultrasound scan; VSL#3, a probiotic mixture of eight bacterial strains. 
Cochrane Risk-of-Bias Tool (0-8): 
A: Random sequence generation. 
B: Allocation concealment. 
C: Blinding of participants and personnel. 
D: Blinding of outcome assessment. 
E: Incomplete outcome data. 
F: Selective reporting. 
G: Other bias 
H: Sample size calculated a priori. 
 
 
 
Table 2. Findings of randomised controlled trials of dietary or lifestyle intervention for 
pediatric NAFLD. ALT, alanine aminotransferase; BMI, body mass index; DHA, 
docosahexaenoic acid; GL, glycemic load; HOMA-IR, homeostatic model of assessment of 
insulin resistance; MRS, magnetic resonance spectroscopy; NA, not assessed; NS, no 
significant difference between control and intervention groups; PUFA, polyunsaturated fatty 
acids; oxLDL, oxidised low-density lipoprotein; SD, standard deviations (of BMI, age-/sex-
corrected); TG, triglycerides; US, ultrasound scan. 
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Table 3. Characteristics of published randomised controlled trials of pharmacological 
interventions for pediatric NAFLD. Maximum Cochrane score is 8, where ≥6 is of high 
quality (HQ). ALT, alanine aminotransferase; BMI, body mass index; DHA, docosahexaenoic 
acid; EPA, eicosapentaenoic acid; IQR, interquartile range; MRI, magnetic resonance 
imaging; MRS, magnetic resonance spectroscopy; NA, not assessed; PLA, placebo; PUFA, 
polyunsaturated fatty acids; oxLDL, oxidised low-density lipoprotein; SD, standard deviations 
(of BMI, age-/sex-corrected); US, ultrasound scan; VSL#3, a probiotic mixture of eight 
bacterial strains. 
Cochrane Risk-of-Bias Tool (0-8): 
A: Random sequence generation. 
B: Allocation concealment. 
C: Blinding of participants and personnel. 
D: Blinding of outcome assessment. 
E: Incomplete outcome data. 
F: Selective reporting. 
G: Other bias 
H: Sample size calculated a priori. 
┼Mixture of: Streptococcus thermophilus, bifidobacteria [B. breve, B. infantis, B. longum], 
Lactobacillus acidophilus, L. plantarum, L. paracasei, and L. delbrueckii subsp. bulgaricus. 
‡Prokid probiotic comprises Lactobacillus acidophilus 3x109 colony forming units (CFU), 
Bifidobacterium lactis 6x109 CFU, Bifidobacterium bifidum 2x109 CFU, and Lactobacillus 
2x109 CFU per capsule.  
 
 
 
Table 4. Findings of randomised controlled trials of pharmacological intervention for 
pediatric NAFLD. ALT, alanine aminotransferase; BMI, body mass index; DHA, 
docosahexaenoic acid; EPA, eicosapentaenoic acid; HDL, high-density lipoprotein; HFF, 
hepatic fat fraction; HOMA-IR, homeostatic model of assessment of insulin resistance; MRI, 
magnetic resonance imaging; MRS, magnetic resonance spectroscopy; NA, not assessed; 
NAS, NASH activity score; NS, no significant difference between control and intervention 
groups; PUFA, polyunsaturated fatty acids; oxLDL, oxidised low-density lipoprotein; SD, 
standard deviations (of BMI, age-/sex-corrected); TG, triglycerides; US, ultrasound scan. 
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Table 5. Protocol primary end-points and interventions for ongoing randomised 
controlled trials in pediatric NAFLD. Adipo-IR, adipose insulin resistance index; alb, 
albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; C’, cholesterol; 
Cath-D, cathepsin-D; CK-18, cytokeratin-18; CRP, C-reactive protein; CVD, cardiovascular 
disease; DXA, dual-energy X-ray absorptiometry; ESR, erythrocyte sedimentation rate; FG, 
fasting glucose; FI, fasting insulin; Hb, hemoglobin; HOMA-IR, homeostatic method of 
assessment of insulin resistance; LPS, lipopolysaccharide; MRE, magnetic resonance 
elastography; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; 
NS, not stated; PDFF, proton density fat fraction; plt, platelets; TNFα, tumour necrosis factor 
alpha; ULN, upper limit of normal. 
┼
 Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire 
assesses anxiety 
‡Chronic Liver Disease Questionnaire (CLDQ) assesses quality of life and University Rhode 
Island Change Assessment Scale (URICA) assesses readiness to change. 
 
 
Supplementary Table 1. Details of end-points, CONSORT checklist reporting, and 
bibliometric data for included studies. Maximum CONSORT score is 25. 
Numbered reporting areas correspond to item numbers on the CONSORT 2010 
Checklist (available at http://www.consort-statement.org/consort- 2010). 
*No primary outcome was defined. ALP, alkaline phosphatase; ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DHA, 
docosahexaenoic acid; EPA, eicosapentaenoic acid; FFA, free fatty acids; FGF19, 
fibroblast growth factor 19; FSH, follicle-stimulating hormone; GGT, gamma-glutamyl 
transferase; GLP-1, glucagon-like peptide-1; HDL, high-density lipoprotein; HOMA-IR, 
homeostatic model of assessment of insulin resistance; hsCRP, high-sensitivity C- 
reactive protein; ISI, insulin sensitivity index; JAMA, Journal of the American Medical 
Association; LDL, low-density lipoprotein; MRI, magnetic resonance imaging; MRS, 
magnetic resonance spectroscopy; N/A, not applicable; NAS, NAFLD activity score; 
NASH, non-alcoholic steatohepatitis; oxLDL, oxidised low-density lipoprotein; PAI1, 
plasminogen activator inhibitor-1; SD, standard deviations (of BMI, age-/sex- 
corrected); TG, triglycerides; QoL, quality of life; ULN, upper limit of normal; US, 
ultrasound 
scan; VLDL, very low-density lipoprotein; WC, waist circumference 
┼
 HOMA-IR was lower in DHA250 group than placebo but not DHA500 group. 
‡ Number of participants with a BMI reduction ≥5% was significantly different between 
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placebo and control groups, but BMI change (as a continuous variable), was not. 
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Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study 
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic review registration number.  
3 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
5 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, 
provide registration information including registration number.  
6 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
6 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched.  
7 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it 
could be repeated.  
7 (& Sup 
Methods) 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
6 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
7 
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Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
7 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether 
this was done at the study or outcome level), and how this information is to be used in any data synthesis.  
7 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  7 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
7 
Section/topic  # Checklist item  Reported 
on page #  
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).  
7 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
- 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
8, & 
SupFig 1 
& 4 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up 
period) and provide the citations.  
8-13 & 
Tables 1 
& 3 & 
SupTable 
1 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  8-13 & 
Tables 1 
& 3 
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Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for 
each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
9-13 & 
Tables 2 
& 4 
SupTable 
1 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  - 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  SupFig2 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see 
Item 16]).  
- 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
14-15 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).  
9-13 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future 
research.  
15 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of 
funders for the systematic review.  
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